Ceo and expert interviews

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) developing new classes of synthetic anti-infectives

31 Mar 2021 - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) CEO and Managing Director James Graham talks about progress with the company's lead anti-infective candidate Recce 327, its expanding portfolio of synthetic anti-infectives targeting viral pathogens and a broad range of bacteria, clinical trial results and priorities for 2021.

Read more...

Immutep (ASX:IMM) LAG-3 validated in Bristol Myers Squibb trial

29 Mar 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma, meeting its primary endpoint of progression-free survival and what it means for Immutep.

Read more...

XTEK (ASX:XTE) 1H21 results & outlook

29 Mar 2021 - XTEK Limited (ASX:XTE) Managing Director Phillipe Odouard talks 1H21 results, discussing the company's expanded operational capacity to meet demand for its high-value proprietary solutions in a favourable market environment for domestic and global defence industries.

Read more...

Market update with Shaw and Partners, March 2021

24 Mar 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses historical precedence for recovering from government spending, the possible rise of interest rates, labour market data, and investment strategies in this environment.

Read more...

Elixinol Global (ASX:EXL) to acquire Cannacare Health

21 Mar 2021 - Elixinol Global (ASX:EXL) CEO, Oliver Horn talks about its proposed acquisition of CannaCare Health GmbH (CannaCare) one of Germany’s leading CBD (Cannabidiol) brands following the down scheduling of CBD in Europe late last year in what the Company sees as highly strategic opportunity and important pathway to profitability.

Read more...

Elixinol Global (ASX:EXL) to acquire Cannacare Health

21 Mar 2021 - Elixinol Global (ASX:EXL) CEO, Oliver Horn talks about its proposed acquisition of CannaCare Health GmbH (CannaCare) one of Germany’s leading CBD (Cannabidiol) brands following the down scheduling of CBD in Europe late last year in what the Company sees as highly strategic opportunity and important pathway to profitability.

Read more...